Future Market Insights analysis suggests that the preclinical antibody development market will increasingly shift toward Asia and emerging biotech hubs as biologics-first pipelines scale and precision research infrastructure deepens. FMI expects the market to evolve from standardized discovery and screening services toward “generative precision platforms” that integrate AI-driven de novo design.